

## University of Groningen

### **Pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes**

Jacobs, Antonius Arnoldus Christiaan; Van der Geize, Robert; Dijkhuizen, Lubbert

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

#### *Document Version*

Publisher's PDF, also known as Version of record

#### *Publication date:*

2010

[Link to publication in University of Groningen/UMCG research database](#)

#### *Citation for published version (APA):*

Jacobs, A. A. C., Van der Geize, R., & Dijkhuizen, L. (2010). Pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes. (Patent No. WO2010079224).

#### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

#### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 July 2010 (15.07.2010)

(10) International Publication Number  
**WO 2010/079224 A1**

PCT

(51) International Patent Classification:  
*A61K 35/74* (2006.01) *A61P 31/04* (2006.01)

(21) International Application Number:  
PCT/EP2010/050196

(22) International Filing Date:  
11 January 2010 (11.01.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/143,869 12 January 2009 (12.01.2009) US  
09150379.7 12 January 2009 (12.01.2009) EP

(71) Applicant (for all designated States except US): **INTER-  
VET INTERNATIONAL B.V.** [NL/NL]; Wim de  
Körverstraat 35, NL-5831 AN Boxmeer (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JACOBS, Antonius  
Arnoldus Christiaan** [NL/NL]; Wim de Körverstraat 35,  
NL-5831 AN Boxmeer (NL). **VAN DER GEIZE, Robert**  
[NL/NL]; University of Groningen, Kerklaan 30,  
NL-9751 NN Haren (NL). **DIJKHUIZEN, Lubbert** [NL/  
NL]; University of Groningen, Kerklaan 30, NL-9751 NN  
Haren (NL).

(74) Agents: **JANSSEN, P. J. P.** et al.; Wim de Körverstraat  
35, NL-5831 AN Boxmeer (NL).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,  
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,  
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,  
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of  
the earlier application (Rule 4.17(iii))

**Published:**

- with international search report (Art. 21(3))
- with (an) indication(s) in relation to deposited biological  
material furnished under Rule 13bis separately from the  
description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PHARMACEUTICAL COMPOSITION TO PROTECT AN ANIMAL AGAINST A DISORDER ARISING FROM  
AN INFECTION WITH A BACTERIUM THAT BELONGS TO THE GROUP OF NOCARDIOFORM ACTINOMYCETES

(57) Abstract: The invention pertains to a pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes having the ability to survive within macrophages of the animal, comprising live bacteria of a nocardioform actinomycetes species, the live bacteria being attenuated by inactivation of a gene that encodes a protein involved in methylhexahydroindanedione propionate degradation, and a pharmaceutically acceptable carrier for these live bacteria.



WO 2010/079224 A1

**Pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform**

**5 actinomycetes**

The present invention pertains to a pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes. The invention also pertains to the use of live attenuated  
10 bacteria of this group to manufacture the said composition and a method of treating an animal with this composition.

Within the bacteria of the class Actinobacteria there is an order of bacteria called Actinomycetales, commonly referred to as actinomycetes. Bacteria that belong to this  
15 order are filamentous gram positive bacteria (several species however have complex cell wall structures which makes classic gram staining less- or even unsuitable, as is for example the case with many species that belong to the Actinomycetales family Mycobacteriaceae) with a high G+C content. They are best known as soil dwelling organisms, although various strains inhabit plants and animals, including humans. They  
20 produce resistant spores which are often attached to aerial mycelium or hyphae. Actinomycetes play an important role in the decomposition of organic material. Several species are used in industry and pharma-research because of their typical properties.

Most actinomycetes are non-pathogenic for animals (the term animals used in  
25 connection with the present invention includes humans). However, within the many suborders of the actinomycetes (i.a. Streptosporangineae, Micrococcineae, Streptomycineae and Frankineae) there is one suborder, viz. the Corynebacterineae, which houses, next to a large amount of non-pathogenic bacteria, a substantial number of animal pathogens. It appears that these pathogens reside within the phylogenic group  
30 known as the nocardioform actinomycetes, which encompasses the families Mycobacteriaceae, Nocardiaceae and Corynebacteriaceae (see i.a. chapter 11, titled: *Rhodococcus equi*: Pathogenesis and Replication in Macrophages, in "Opportunistic Intracellular Bacteria and Immunity", by Lois J. Paradise et al (eds.), New York, 1999). Remarkably, against the larger part of diseases related to infection with these  
35 pathogens there is hardly any adequate prophylactic treatment (i.e. treatment prior to, or essentially at the same time as exposure to the disease causing pathogen which may

either be able to prevent the disease from being contracted, or at least mitigate the effects of the disease) available. During recent years the recognition that the families Mycobacteriaceae, Nocardiaceae and Corynebacteriaceae of the phylogenetic group of nocardioform actinomycetes are very closely related families within the suborder of the Corynebacterineae, has been confirmed (see also University of California, San Diego, Outline of Senior Project, Marelle L. Yehuda, June 2, 2005). It has also become clear that in particular the pathogenic bacteria in this group, at least the ones for which no adequate prophylactic treatment is available (such as for example *Mycobacterium tuberculosis*, *Nocardia seriolae* and *Rhodococcus equi*), have an important property in common: infection typically occurs via skin or mucous membrane, followed by dissemination of the bacteria within macrophages and replication within these macrophages (see i.a. Microbes and Infection 7, 2005, 1352-1363; Proceedings of the National Academy of Sciences, June 7, 2005, Vol. 102, no 23, pp 8327 – 8332; Nature Medicine 13, 282 – 284, 2007; Transplantation Proceedings, Volume 36, Issue 5, June 2004, pp 1415 – 1418). Indeed macrophages are at the frontline of host immune defence against microbial infections, but unlike bacteria that depend on the avoidance of phagocytosis to survive in the host, the currently contemplated pathogenic bacteria within this group target macrophages to survive and even replicate in the host. The present invention is concerned with these bacteria that have the ability to survive within macrophages of an animal, and in connection with the current invention will be referred to as macrophage surviving nocardioform actinomycetes.

Apparently, the macrophage surviving nocardioform actinomycetes have evolved to evade critical functions of an animal's defence against microbes. In particular *Mycobacterium tuberculosis*, the causative microbe of tuberculosis, is a species that has successfully exploited macrophages as its primary niche in vivo, but other bacterial species that belong to the group of nocardioform actinomycetes, including Mycobacteriaceae, Nocardiaceae and Corynebacteriaceae, have adopted the same strategy. These are for example *Mycobacterium ulcerans* that causes Buruli ulcer, *Mycobacterium avium paratuberculosis* that causes Johne's disease in cattle and which is linked to Crohn's disease in humans, *Mycobacterium bovis* that causes bovine tuberculosis, *Mycobacterium avium* which is related to opportunistic infection of immunocompromised subjects such as AIDS-patients, *Nocardia seriolae* and *Nocardia farcinia* that cause nocardiosis in fish, *Nocardia asteroides* which causes infection in renal transplant recipients, *Rhodococcus equi* (formerly known as *Corynebacterium*) that causes pneumonia in foals and which is also connected to opportunistic infections

in immunocompromised subjects, *Corynebacterium pseudotuberculosis* that causes abscesses, i.a. in the lungs, in sheep, goats, horses and occasionally also in humans, etc. All of these bacterial species have in common the ability to survive within macrophages, infect them and replicate within this type of host cell.

5

This typical property seriously hampers the treatment for disorders (in this specification the term "disorder" is used as an equivalent for "disease") arising from an infection with a bacterium that belongs to the group of macrophage surviving nocardioform actinomycetes. In many cases, treatment is with antibiotics when clinical signs are actually present. This however is cumbersome since a significant amount of the bacteria are present within macrophages and hard to reach by antibiotics. Treatment with antibiotics therefore often takes a long treatment time, and with mixed success. For diseases such as tuberculosis in humans, nocardiosis in fish and pneumonia in foals, prophylactic treatment would be preferred. Such prophylactic treatment typically relies on the use of a vaccine comprising killed or live attenuated bacteria derived from wild type bacteria. With regard to the macrophage surviving nocardioform actinomycetes, killed vaccines (i.e vaccines comprising killed bacteria or one or more subunits thereof as the therapeutic agent) have proven to be unsuccessful. At present it is generally believed that one needs live bacteria for a successful prophylactic treatment against macrophage surviving nocardioform actinomycetes, since only these can have the capability of reaching the macrophages and mimic wild-type bacteria sufficiently to trigger an adequate immune response. Indeed, to treat tuberculosis, a live vaccine (BCG, Bacille Calmette Guérin) is available based on the species *Mycobacterium bovis* which species is very closely related to the species *Mycobacterium tuberculosis*. However, the protective effect is not impressive. With regard to Nocardiaceae species such as *Rhodococcus equi* and *Nocardia seriolae*, no vaccines are currently commercially available. With regard to the species *Corynebacterium pseudotuberculosis* control has been attempted using autogenous vaccines, however with mixed success (RUMA Guidelines, National Office of Animal health, Hertfordshire, United Kingdom, 2006).

There is clearly a need for adequate prophylactic treatment to protect an animal against a disorder arising from an infection with macrophage surviving nocardioform actinomycetes. Treatment in this sense means stimulating the immune system of the target animal sufficiently to at least reduce the negative effects of a challenge with wild-type micro-organisms. The goal is that this leads to a protection against the disorder, i.e.

the disorder is prevented, or at least the level of infection or the clinical signs of disease in the animal are diminished, and consequently the severity of disease is diminished as well. The fact that the macrophage surviving nocardioform actinomycetes have adopted the same strategy for surviving in a host brings about the idea of a common strategy for prophylactic treatment against an infection with these bacteria.

In this respect it is noted that it has been described in literature that cholesterol metabolism plays a crucial role in the survival of nocardioform actinomycetes in macrophages and might be an important virulence factor (Proceedings of the National Academy of Science, February 6, 2007, vol. 104, no. 6, pp 1947-1952). It was also suggested that this metabolism provides logical targets for novel therapeutic agents to combat disease causing strains, i.e. drugs for treatment after infection has occurred. Indeed, when applying hindsight there is other supporting evidence for the established fact that for all macrophage surviving nocardioform actinomycetes, cholesterol metabolism plays a role in the survival and persistence of the bacteria in host macrophages. For example, from chapter 11 (titled: *Rhodococcus equi*: Pathogenesis and Replication in Macrophages) in "Opportunistic Intracellular Bacteria and Immunity", by Lois J. Paradise et al (eds.), New York, 1999 it is known that there are great similarities in the clinical symptomatology between infections caused by several nocardioform actinomycetes and cholesterol oxidase was determined to be an enzymatic component of virulence factors. In Veterinary Microbiology, Volume 56, Issue 3-4, June 1997, 269-276 it is shown that *Corynebacterium pseudotuberculosis* is involved in the cholesterol oxidase process together with *Rhodococcus equi*.

Therefore, at first glance it seems tempting to develop a pharmaceutical composition to protect an animal against a disorder arising from an infection with macrophage surviving nocardioform actinomycetes (such a composition can also be referred to as a vaccine), using the recognition that cholesterol metabolism plays a crucial role in the survival of these bacteria in the macrophages. However, once realising that the suggestions made in the PNAS article referred to here-above (2007 article) related to a drug, and thus aimed at completely killing the bacteria by interfering in their cholesterol metabolism, pursuing that same strategy seems to be unsuitable for a live vaccine: if one tries to attenuate a bacterium by cutting off its survival at the essential site of replication, the bacterium will not replicate and persist in the host animal. Indeed, for a treatment with drugs this is an ideal situation. However, for a live vaccine, if one completely blocks survival of the bacterium, one expects to mimic a vaccine comprising killed bacteria.

Such vaccines have proven to be unsuccessful for treating macrophage surviving nocardioform actinomycetes. Still, attempts have been performed to assess the use of live bacteria that are crippled in their cholesterol metabolism, in a pharmaceutical composition for protecting an animal against a challenge with wild type disease causing nocardioform actinomycetes. An example of such attempts is a live vaccine based on a cholesterol oxidase (ChoE) mutant of wild type *Rhodococcus equi* strain 103+ (Prescott in Veterinary Microbiology 118, 2006, pp 240-246). This attempt was unsuccessful. However, not because it induced no protection, as one would expect based on the technical teachings of the PNAS article as referred to here-above (PNAS February 6, 2007, vol. 104, no. 6, pp 1947-1952), but because the mutant strain was still too virulent. The mutant could still survive and multiply in macrophages at a level comparable to wild-type *R. equi*. Also, the antigenic load of this cholesterol cripple mutant appeared to be comparable with that of a wild-type organism. Therefore, the mutant was still capable of inducing disease. Indeed, in the mean time it has also been established that a live mutant *Rhodococcus equi* that is unable to take up cholesterol at all (sterol uptake permease mutant *supAB* as presented by Van der Geize et al. at the 4<sup>th</sup> Havemeyer Workshop on *Rhodococcus equi*, Edinburgh, 13-16 July, 2008; and Van der Geize et al.: "A novel method to generate unmarked gene deletions in the intracellular pathogen *Rhodococcus equi* using 5-fluorocytosine conditional lethality" in Nucleic Acids Research 2008; doi: 10.1093/nar/gkn811, further on also referred to as "Van der Geize *et al.*, 2008"), which means that the complete cholesterol metabolism is blocked (at least when cholesterol is used as the starting compound), is still capable of surviving and persisting in macrophages (Van der Geize *et al.*, 2008) and thus is still too virulent. In order to attenuate a live *Rhodococcus equi* one appears to need an additional mutation having an effect outside the cholesterol metabolism (Prescott: Veterinary Microbiology 125, 2007, 100-110). Based on these results, it was concluded that cholesterol metabolism as such is not an important virulence factor and cannot be used to sufficiently attenuate these bacteria. Bacteria having mutations in their cholesterol metabolism apparently have the same, or at least a comparable antigenic load as the wild type organism and thus, although capable of providing adequate protection (that is: if the subject animal survives the challenge with the mutated bacteria), are far too virulent to be used in a pharmaceutical composition. Thus, targeting at a pharmaceutical composition for prophylactic treatment, which composition contains live bacteria that are attenuated by inactivating genes involved in the cholesterol metabolism, is thought to be a dead end street.

Surprisingly however applicant found that in order to protect an animal against a disorder arising from an infection with a macrophage surviving nocardioform actinomycete, one can use a pharmaceutical composition comprising live bacteria of a nocardioform actinomycetes species (typically being of the same species as the  
5 infecting bacterium or alternatively, being of a very closely related species, thus having many T-cell epitopes in common such as is the case with *Mycobacterium tuberculosis* vs *Mycobacterium bovis*), the live bacteria are attenuated by inactivation of a gene that encodes a protein involved in methylhexahydroindanedione propionate degradation, and a pharmaceutically acceptable carrier for carrying the bacteria.

10

“Attenuated” in this sense means being incapable of inducing a full suite of symptoms of the disease that is normally associated with the virulent (often wild-type) pathogenic counterpart of the attenuated bacterium.

“Inactivation” in the sense of the present invention means that a gene, for example while  
15 being part of an operon (i.e. the set of genes necessary to actually express the protein at a functional level) is either removed completely from the genome or changed (by any known, or even yet to be devised technique; see e.g. Introduction to Biotechnology and Genetic Engineering, A.J. Nair, INFINITY SCIENCE PRESS LLC, 2008, chapter 13 “Genetic Techniques”, pp 476-496 and chapter 15 “Recombinant DNA Technology”, pp  
20 563-612) such that it no longer encodes the corresponding wild-type protein, or is no longer accessible for complete transcription, or any other change in the genome such that the wild-type protein will not be made by the attenuated bacterium *in vivo*, at least not at level suitable to support normal methylhexahydroindanedione propionate catabolism when compared to a situation wherein the gene (or operon, if applicable) is  
25 in a form suitable to support normal metabolism.

“Encoding a protein” in the sense of the present invention means that the gene (for example while being part of an operon) directly encodes the protein or a subunit of the protein (multiple subunits together forming the enzymatically active protein), or encodes one or more intermediates that are converted, either directly or via multiple steps, in the  
30 protein or subunit thereof (multiple subunits together forming the enzymatically active protein).

A “pharmaceutically acceptable carrier” can be any solvent, dispersion medium, coating, antibacterial and antifungal agent, isotonic and absorption delaying agent, and the like that are physiologically compatible with and acceptable for the target animal, e.g. by  
35 being made i.a. sterile. Some examples of such carrying media are water, saline, phosphate buffered saline, bacterium culture fluid, dextrose, glycerol, ethanol and the



like, as well as combinations thereof. They may provide for a liquid, semi-solid and solid dosage form, depending on the intended mode of administration. As is commonly known, the presence of a carrying medium is not essential to the efficacy of a vaccine, but it may significantly simplify dosage and administration of the antigen. Next to the carrier and antigen, the pharmaceutical composition may comprise other substances such as adjuvants, stabilisers, viscosity modifiers or other components are added depending on the intended use or required properties of the composition.

In the pharmaceutical composition of the present invention, live bacteria are present, which bacteria are mutated such that a gene that encodes a protein involved in methylhexahydroindanedione propionate degradation is inactivated. As is commonly known, methylhexahydroindanedione propionate (also known as HIP or  $3\alpha$ -H- $4\alpha$ -(3'-propionic acid)- $7\alpha\beta$ -methylhexahydro-1,5-indanedione) and 5-hydroxy-methylhexahydroindanone propionate (also known as HIL or  $3\alpha$ -H- $4\alpha$ -(3'-propionic acid)- $5\alpha$ -hydroxy- $7\alpha\beta$ -methylhexahydro-1-indanone- $\delta$ -lactone) are formed during the degradation of cholesterol by actinobacteria, including the macrophage surviving nocardioform actinomycetes. Recently, an operon (called ipdAB: indanedione propionate degradation Alfa + Beta) has been identified in bacterial species that belong to the suborder of Corynebacterineae that encodes the  $\alpha$  and  $\beta$  subunit of a transferase that is involved in HIP degradation (see co-pending International Patent application PCT/EP2008/060844, filed 19 August 2008, based on a US priority application filed 21 August 2007). The known transferase knock out mutant is no longer capable of degrading HIP and HIL (see figure 3 of the patent application referred to here-above) nor does it grow on HIP, HIL or 4-androstene-3,17-dione. In any case, "involved in HIP degradation" means that a knock out mutant is no longer capable of growth on HIP as a sole carbon and energy source, or at least not capable of growth on HIP at a level obtainable by a non-mutant bacterium. At present it is not clear whether the transferase catabolises HIP degradation itself or whether a reaction is catalysed on which HIP degradation depends. Still, HIP degradation occurs at a relatively late stage in the cholesterol metabolism and is a very specific step in the cholesterol degradation pathway. Based on the publicly available knowledge about mutations in the cholesterol metabolism (Prescott references mentioned here-above), one would expect that this mutation would lead to a live bacterium that, although providing a protective effect, would be far too virulent. To applicant's surprise however, such a mutant appears to be adequately attenuated which is due to significantly reduced survival capabilities of the mutant within macrophages. The reason why a gene that is involved in HIP degradation

plays such an important role in survival within macrophages is unclear. It even seems to contradict prior art results which show that even a complete blockade of cholesterol metabolism has a poor attenuating effect, apparently since there is no effect on the macrophage survival capabilities of the nocardioform actinomycetes. Therefore, it was quite surprising to find that the present mutation, which affects a minor step along the pathway of cholesterol catabolism, severely hampers the survival capabilities of pathogenic nocardioform actinomycetes in macrophages. In particular, it has been found that the mutant live bacteria are still able to enter the macrophages and persist in them (hence securing the stimulus of a protective immune response), but at a very low level, which appears to significantly reduce their virulence, which on its turn makes them acceptable for prophylactic treatment.

In an embodiment, multiple genes in one operon are inactivated. By inactivating multiple genes the chances of a change of the bacterium to a wild-type (resembling) phenotype will decrease. In particular, the genes *ipdA* and *ipdB* are inactivated. By inactivating these genes, an effective and safe attenuation can be provided for. In a preferred embodiment the inactivation is realised by deleting at least one gene by unmarked gene deletion. An advantage of unmarked mutation is that it allows the repetitive introduction of mutations in the same strain. Foreign DNA (vector DNA) is removed in the process of introducing the mutation. Newly introduced vector DNA, for the introduction of a second mutation, therefore cannot integrate at the site of the previous mutation (by homologous recombination between vector DNA's). Integration will definitely happen if vector DNA is still present in the chromosome and will give rise to a large number of false-positive integrants. The system enables the use of a sole antibiotic gene for the introduction of an infinite number of mutations. Unmarked mutation also allows easy use in the industry because of the absence of heterogeneous DNA allowing easy disposal of fermentation broth. Gene inactivation by gene deletion enables the construction of stable, non-reverting mutants. Especially small genes (<500 bp) are inactivated more easily by gene deletion compared to gene disruption by a single recombination integration. Gene deletion mutagenesis can also be applied to inactivate a cluster of several genes from the genome. The gene deletion mutagenesis strategy can be applied also for gene-replacement (e.g. changing wild type into mutant gene).

In an embodiment the bacteria belong to the family of Nocardiaceae or Mycobacteriaceae. Preferably, the bacteria belong to the genera *Rhodococcus*, *Nocardia* or *Mycobacterium* and in particular belong to any of the species *Rhodococcus*

*equi*, *Nocardia seriolae*, *Mycobacterium tuberculosis*, *Mycobacterium ulcerans*,  
*Mycobacterium bovis* or *Mycobacterium avium paratuberculosis*. With regard to these  
species, adequate vaccines are not commercially available to date. The present  
invention allows the provision of pharmaceutical compositions that can be used as  
5 vaccines to combat these bacteria and therefore mitigate the corresponding diseases  
they cause in an animal.

In an embodiment the pharmaceutical composition is in a form suitable for oral  
administration. Besides the fact that it is a very convenient way of administration , it has  
10 in particular become clear that this way of administration is safe. Parenteral  
administration may give rise to abscesses. Preferably the live bacteria are present in a  
concentration between  $1 \times 10^4$  and  $1 \times 10^{10}$  CFU per dose.

The present invention also pertains to *Rhodococcus equi* bacteria derived from a strain  
15 as deposited with the Collection Nationale de Cultures de Micro-organismes of the  
Institut Pasteur at Paris France under nr. CNCM I-4108 or nr. CNCM I-4109.  
and to bacteria that belong to this strain.

The present invention also pertains to the use of live bacteria that belong to the group of  
20 nocardioform actinomycetes having the ability to survive within macrophages of an  
animal, the live bacteria being attenuated by inactivation of a gene that encodes a  
protein involved in methylhexahydroindanedione propionate degradation, to  
manufacture a pharmaceutical composition to protect an animal against a disorder  
arising from an infection with a corresponding wild-type bacterium.

25 The invention also pertains to a method of treating an animal to protect it against a  
disorder arising from an infection with a bacterium that belongs to the group of  
nocardioform actinomycetes having the ability to survive within macrophages of an  
animal, comprising administering to the animal a pharmaceutical composition  
30 comprising live bacteria of a nocardioform actinomycetes species, which live bacteria  
are attenuated by inactivation of a gene that encodes a protein involved in  
methylhexahydroindanedione propionate degradation.

The invention will be further explained using the following examples describing specific  
35 embodiments of the present invention, which embodiments are spread over three parts:

**Part A:** Identification and construction of strains

**Part B:** Macrophage survival as a model for *in vivo* attenuation

**Part C:** Efficacy of mutant bacteria in protection against infection with wild-type

5

## **PART A: IDENTIFICATION AND CONSTRUCTION OF STRAINS**

### **A1 Culture media and growth conditions**

- 10 *R. equi* strains were grown at 30°C (200 rpm) in Luria-Bertani (LB) medium consisting of Bacto-Tryptone (BD), Yeast Extract (BD) and 1% NaCl (Merck) or mineral acetate medium. *M. smegmatis* mc<sup>2</sup>155 (Snapper *et al.*, 1990, *Mol. Microbiol.* **4**:1911-1919) was grown at 37°C (200rpm) in BBL trypticase soy broth (TSB; BD) supplemented with 0.05% Tween80. Mineral acetate medium (MM-Ac) contained K<sub>2</sub>HPO<sub>4</sub> (4.65 g/l),
- 15 NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O (1.5 g/l), Na-acetate (2 g/l), NH<sub>4</sub>Cl (3 g/l), MgSO<sub>4</sub>·7H<sub>2</sub>O (1 g/l), thiamine (40 mg/l, filter sterile; Sigma), and Vishniac stock solution (1 ml/l). Vishniac stock solution was prepared as follows (modified from Vishniac and Santer, 1957, *Rev.* **21**: 195–213): EDTA (10 g/l) and ZnSO<sub>4</sub>·7H<sub>2</sub>O (4.4 g/l) were dissolved in distilled water (pH 8 using 2 M KOH). Then, CaCl<sub>2</sub>·2 H<sub>2</sub>O (1.47 g/l), MnCl<sub>2</sub>·7 H<sub>2</sub>O (1 g/l), FeSO<sub>4</sub>·7 H<sub>2</sub>O (1
- 20 g/l), (NH<sub>4</sub>)<sub>6</sub> Mo<sub>7</sub>O<sub>24</sub>·4 H<sub>2</sub>O (0.22 g/l), CuSO<sub>4</sub>·5 H<sub>2</sub>O (0.315 g/l) and CoCl<sub>2</sub>·6 H<sub>2</sub>O (0.32 g/l) were added in that order at pH 6 and finally stored at pH 4.
- For growth on solid media Bacto-agar (15 g/l; BD) was added. 5-Fluorocytosine (Sigma-Aldrich) stock solution (10 mg/ml) was prepared in distilled water, dissolved by heating to 50°C, filter-sterilized and added to autoclaved media.
- 25 *Nocardia seriolae* strain INS436 was routinely grown at 26°C (200 rpm) in Eugon Broth (BD) supplemented with Tween80 (0.05%). For growth on solid media Bacto-agar (15 g/l; BD) was added. Sucrose (2%) was added to the agar medium for *sacB* dependent sucrose selection.

30

### **A2 Identification of *ipdA*, *ipdB* and *fadE30* in *R. equi* strain 103+, and *ipdAB* in *N. seriolae* INS436**

- As indicated here-above, the *ipdA* and *ipdB* genes of *Rhodococcus* are found to be
- 35 involved in the degradation of methylhexahydroindanedione propionate (HIP; 3α-H-

4 $\alpha$ (3'-propionic acid)-7 $\alpha$ -methylhexahydro-1,5-indanedione) and 5-hydroxy-methylhexahydroindanone propionate (HIL; 3 $\alpha$ -H-4 $\alpha$ (3'-propionic acid)-5 $\alpha$ -hydroxy-7 $\alpha$ -methylhexahydro-1-indanone- $\delta$ -lactone). Bioinformatics analyses of the protein sequences of *lpdA* and *lpdB* of *R. erythropolis* strain SQ1 in genome databases

5 revealed that the genes encoding *lpdA* and *lpdB* and their apparent operonic organization were conserved in the genome of *R. equi* 103+ (wild-type strain obtained from J.F. Prescott, Ontario, Canada; as referred to in Veterinary Microbiology **118** (2006) 240-246). The *R. equi* 103+ genome sequence has been determined by the *R. equi* sequencing group at the Sanger Institute, Hinxton, Cambridge, UK (genome

10 published as "*R. equi* 103S"). Genome analysis furthermore revealed that *R. equi* 103+ harbors additional paralogous genes of *ipdA* and *ipdB*, designated *ipdA2* and *ipdB2*, respectively. These genes are located outside the cholesterol catabolic gene cluster. The amino acid sequences of *lpdA*, *lpdB*, *ipdA2* and *ipdB2* are depicted in the appended SEQ ID's under No 1, 2, 3 and 4 respectively. Amino acid sequence identities

15 of the *lpdA* and *lpdB* proteins of *R. equi* 103+ with these paralogues and several other actinobacterial orthologues are listed in Table 6. This table gives an overview of genes identified in other genomes of nocardioform actinomycetes, encoding orthologues of *lpdA* and *lpdB* of *Rhodococcus equi* 103+. In connection with the present invention, these and other orthologues are called *lpdA* and *lpdB*. Protein identity indicates

20 percentage full length amino acid sequence identity with *lpdA* and *lpdB* of *R. equi* 103S. Actinobacterial genome sequences were obtained from the genomic BLAST server for microbial genomes of the National Center for Biotechnology Information (NCBI). The *R. equi* 103+ sequence data were produced by the *R. equi* Sequencing Group at the Sanger Institute. The genome of strain 103+ (known as 103S) was used for these

25 identificaton purposes. Practical work with *Rhodococcus equi*, as exemplified hereafter, was carried out with *R. equi* strain RE1 (isolated from a foal suffering from granulomatous pneumonia caused by *Rhodococcus equi* infection).

A second gene involved in the degradation of methylhexahydroindanedione propionate

30 is *fadE30*. The  $\Delta$ *fadE30* mutant is severely impaired in growth on HIL and HIP, showing virtually no growth after 24 hours of incubation. The *fadE30* gene of *Rhodococcus equi* was identified by a protein sequence similarity search performed on the *R. equi* 103+ genome available at the Sanger Institute (<http://www.sanger.ac.uk>). The annotated protein sequence of *FadE30* of *Rhodococcus jostii* strain RHA1 (Ro4596, Genbank

35 accession number ABG96382) was used as a protein sequence template (McLeod *et al.*, 2006, in *Proc. Natl. Acad. Sci. U.S.A.* **103**:15582-15587; and Van der Geize *et al.*,

2007, in *Proc. Natl. Acad. Sci. U.S.A.* **104**:1947-1952). A database similarity search with Ro04596 revealed a gene of *R. equi* 103S, encoding a protein that displayed 73% amino acid sequence identity to Ro04596. This protein was annotated as FadE30 of *R. equi* 103S (SEQ ID No 43) and its corresponding gene was termed *fadE30*. Orthologous  
 5 genes, encoding FadE30 in other actinobacteria, could be identified in a similar way. A selection of these is listed in Table 8.

The *ipdAB* genomic locus of *N. seriola* was amplified by PCR in three parts, using oligonucleotide primers developed on highly conserved nucleotide sequences of the  
 10 actinobacterial *ipdAB* locus. These conserved regions were identified by nucleotide sequence alignment of several known actinobacterial sequences of the *ipdAB* genes. The nucleotide genome sequence of the *ipdAB* region of *Nocardia farcinica* (*nfa05080-nfa05090*) (DDBJ accession number AP006618) was used as a primary template to develop the oligonucleotide PCR primers. The primer oligonucleotide sequences used  
 15 are listed in Table 5. Chromosomal DNA of *N. seriola* INS436 was used as template for PCR. The *ipdAB* genes of *N. seriola* were amplified using primers ipdA-actino-F and ipdB-actino-R (PCR 22), the upstream region of *ipdAB* was amplified using ipd-actino-F2 and ipdA-actino-R (PCR 23), and the downstream region was amplified using ipdB-actino-F and ipd-actino-R (PCR 21). PCR products were cloned into the pGEM-T  
 20 cloning vector and the nucleotide sequences of the inserts were determined. Different primer pairs were subsequently developed on the obtained DNA sequence and used to re-clone and re-sequence the *ipd* locus. This resulted in a complete nucleotide sequence of the *ipdAB* locus of *N. seriola* covering 4,139 bp. The sequenced DNA fragment contained the *ipdA* and *ipdB* genes of *N. seriola* and their neighboring genes.  
 25 The deduced protein sequences of IpdA and IpdB of *N. seriola* INS436 are shown in SEQ ID NO 58 and SEQ ID NO 59 respectively.

### **A3 Cloning, PCR and genomic DNA isolation**

30

*Escherichia coli* DH5 $\alpha$  was used as host for all cloning procedures. Restriction enzymes were obtained from Fermentas GmbH. Chromosomal DNA of cell cultures was isolated using the GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich) according to the instructions of the manufacturer.

35 PCR was performed in a reaction mixture (25  $\mu$ l) consisting of Tris-HCl (10 mM, pH 8), 1x standard polymerase buffer, dNTPs (0.2 mM), DMSO (2%), PCR primers (10 ng/ $\mu$ l

each, Table 5) and High-Fidelity DNA polymerase enzyme (Fermentas) or Pwo DNA polymerase (Roche Applied Science). For colony PCR, cell material was mixed with 100 µl of chloroform and 100 µl of 10 mM Tris-HCl pH 8, vortexed vigorously and centrifuged (2 min, 14,000 x g). A sample of the upper water phase (1 µl) was subsequently used as  
5 template for PCR. A standard PCR included a 5 min 95°C DNA melting step, followed by 30 cycles of 45 sec denaturing at 95°C, 45 sec annealing at 60°C and 1-3 min elongation at 72°C. The elongation time used depended on the length of the expected PCR amplicon, taking 1.5 min/1 kb as a general rule.

10

#### **A4 Electrotransformation of *R. equi*, *M. smegmatis* and *N. seriolae***

Cells of *R. equi* strains were transformed by electroporation essentially as described (Van der Geize *et al.*, in the accepted *NAR* paper referred to here-above; Navas *et al.*,  
15 2001, *J. Bacteriol.* **183**: 4796-4805). Briefly, cell cultures were grown in 50 ml LB at 30°C until OD<sub>600</sub> reached 0.8-1.0. The cells were pelleted (20 min at 4,500 x g) and washed twice with 10% ice-cold glycerol. Pelleted cells were re-suspended in 0.5-1 ml ice-cold 10% glycerol and divided into 200 µl aliquots.

Cells of *M. smegmatis* mc<sup>2</sup>155 were transformed by electroporation essentially as  
20 described (Jacobs *et al.*, 1991, *Methods Enzymol.* **204**:537-555). Briefly, cell cultures (250 ml) were grown at 37°C in TSB medium + 0.05% Tween80 until OD<sub>600</sub> reached 0.8, put on ice for one and a half hour and centrifuged (10 min at 5,000 x g) to pellet the cells. Cell pellets were washed twice with distilled water and resuspended in a final volume of 1 ml 10% glycerol and divided into 200 µl aliquots.

25 MilliQ-eluted plasmid DNA (5-10 µl; GenElute Plasmid Miniprep Kit, Sigma-Aldrich) was added to 200 µl cells in 2 mm gapped cuvettes. Electroporation was performed with a single pulse of 12.5 kV/cm, 1000Ω and 25 µF. Electroporated cells were gently mixed with 1 ml LB medium (*R. equi*) or 1 ml TSB + 0.05% Tween80 (*M. smegmatis*) and allowed to recover for 2 h (*R. equi*) or 5 h (*M. smegmatis*) at 37°C and 200 rpm. Aliquots  
30 (200 µl) of the recovered cells were plated onto selective agar medium. *R. equi* transformants were selected on LB agar containing apramycin (50 µg/ml) and appeared after 2-3 days of incubation at 30°C. *M. smegmatis* transformants were selected on TSB + 0.05% Tween80 agar containing kanamycin (10 µg/ml) and appeared after 4-5 days of incubation at 37°C.

35

For *N. seriola*, a pre-culture (20 ml) of strain INS436 was grown for 5 days at 26°C (200 rpm) in Eugon broth + 0.05% Tween80 (OD<sub>600nm</sub> = 6) and used to inoculate 100 ml of fresh Eugon broth + 0.05% Tween80 medium (1:100). The primary culture was grown overnight at 26°C for 20 hours to OD<sub>600nm</sub> = 1.3.

- 5 The cells were pelleted (20 min, 4000g) at 4°C and washed twice with 50 ml ice-cold 10% glycerol. The pelleted cells were resuspended in 500 µl 10% glycerol, divided into 200 µl aliquots and immediately used for electrotransformation. MilliQ-eluted plasmid DNA (5-10 µl; GenElute Plasmid Miniprep Kit, Sigma-Aldrich) was added to 200 µl cells in a 2 mm gapped cuvette, mixed and left for 1 min on ice. Electroporation was
- 10 performed with a single pulse of 1.75 kV/cm, 200Ω and 50 µF (approx. time pulse 9.3 ms). Electroporated cells were gently mixed with 1 ml Eugon broth medium supplemented with 0.05% Tween80 and allowed to recover for 3.5 h at 26°C and 220 rpm. Aliquots of 50 and 100 µl of the recovered cells were plated onto selective Eugon agar supplemented with 0.05% Tween80 and kanamycin (20 µg/ml). Transformants
- 15 appeared after 7 days of incubation at 26°C.

#### **A5 Unmarked gene deletion in *R. equi* strains using 5-fluorocytosine (5-FC) selection**

- 20 Unmarked gene deletion mutants of *R. equi* were made essentially as described (Van der Geize *et al.*, 2008). *R. equi* transformants obtained from electroporation of wild type or mutant cells were streaked onto LB agar medium supplemented with apramycin to
- 25 confirm apramycin resistance (Apra<sup>R</sup>). Four Apra<sup>R</sup> transformants per transformation were grown overnight (20-24 h) at 30°C and 200 rpm in 25 ml LB medium, and plated in 10<sup>1</sup>-10<sup>3</sup> fold dilutions in MM-Ac medium onto MM-Ac agar plates supplemented with 5-FC (100 µg/ml) in 100 µl aliquots. 5-FC resistant colonies, appearing after 3 days of incubation at 30°C, were replica streaked onto LB agar and LB agar supplemented with
- 30 apramycin (50 µg/ml) to select for apramycin sensitive (Apra<sup>S</sup>) and 5-FC resistant (5-FC<sup>R</sup>) colonies. Apra<sup>S</sup>/5-FC<sup>R</sup> colonies were checked for the presence of the desired gene deletion by colony PCR using primers amplifying the locus of the gene deletion (Table 5). Genomic DNA was isolated from potential gene deletion mutants and used to
- 35 confirm the gene deletion using primers amplifying the *ipdAB* or *ipdAB2* gene locus, as well as the upstream and downstream regions of these loci with primers as described in Table 5.



**A6 Construction of plasmids for ipdAB and ipdAB2 gene deletion in *R. equi***

5 Plasmid pSelAct-ipd1, for the generation of an unmarked gene deletion of the *ipdAB* operon in *R. equi* RE1, was constructed as follows. The upstream (1,368 bp; primers ipdABequiUP-F and ipdABequiUP-R) and downstream (1,396 bp; primers ipdABequiDOWN-F and ipdABequiDOWN-R) flanking regions of the *ipdAB* genes were amplified by PCR (Table 5, PCR1 and PCR2). The obtained amplicons were ligated into  
 10 *EcoRV* digested pBluescript(II)KS, rendering plasmids pEqui14 and pEqui16 for the upstream and downstream region, respectively. A 1.4 kb *SpeI/EcoRV* fragment of pEqui14 was ligated into *SpeI/EcoRV* digested pEqui16, generating pEqui18. A 2.9 kb *EcoRI/HindIII* fragment of pEqui18, harboring the *ipdAB* gene deletion and its flanking regions, was treated with Klenow fragment and ligated into *SmaI* digested pSelAct  
 15 suicide vector (Van der Geize *et al.*, 2008). The resulting plasmid was designated pSelAct-ipd1 for the construction of *ipdAB* gene deletion mutant *R. equi*  $\Delta$ ipdAB (also referred to as RG1341). This mutant was deposited at the Collection Nationale de Cultures de Micro-organismes of the Institut Pasteur at Paris France under nr. CNCM I-4108.

20

Double gene deletion mutant *R. equi*  $\Delta$ ipdAB $\Delta$ ipdAB2 (also referred to as RG2837) was made by unmarked gene deletion of the *ipdAB2* operon in *R. equi*  $\Delta$ ipdAB mutant strain using plasmid pSelAct- $\Delta$ ipdAB2. Plasmid pSelAct- $\Delta$ ipdAB2 was constructed as follows. The upstream (1,444 bp; primers ipdAB2equiUP-F and ipdAB2equiUP-R) and  
 25 downstream (1,387 bp; ipdAB2equiDOWN-F, ipdAB2equiDOWN-R) regions of *ipdAB2* were amplified by PCR using genomic DNA as template (Table 5, PCR6 and PCR7). The amplicons were ligated into *SmaI* digested pSelAct, resulting in plasmids pSelAct-ipdAB2equiUP and pSelAct-ipdAB2equiDOWN, respectively. Following digestion with *BglII/SpeI* of both plasmids, a 1,381 bp fragment of pSelAct-ipdAB2equiDOWN was  
 30 ligated into pSelAct-ipdAB2equiUP, resulting in pSelAct- $\Delta$ ipdAB2 used for the construction of a  $\Delta$ ipdAB2 gene deletion. The resulting mutant *R. equi*  $\Delta$ ipdAB $\Delta$ ipdAB2 was deposited at the Collection Nationale de Cultures de Micro-organismes of the Institut Pasteur at Paris France under nr. CNCM I-4109

35

**A7 Construction of plasmid for ipdAB gene deletion in *M. smegmatis* mc<sup>2</sup>155**

Plasmid pK18-ipdABsmeg, used for the unmarked gene deletion of the *ipdAB* genes in  
 5 *M. smegmatis* mc<sup>2</sup>155 was constructed as follows.  
 The upstream (1,502 bp; primers ipdABsmegUP-F and ipdABsmegUP-R) and  
 downstream (1,431 bp; primers ipdABsmegDOWN-F and ipdABsmegDOWN-R) flanking  
 regions of the *ipdAB* genes were amplified by PCR using genomic DNA of *M.*  
*smegmatis* mc<sup>2</sup>155 as template (Table 5, PCR12 and PCR13). The obtained amplicons  
 10 were ligated into *Sma*I digested pK18mobsacB (Schäfer et al., 1994, *Gene* **145**:69-73),  
 resulting in pK18-ipdABsmegUP and pK18-ipdABsmegDOWN, respectively. A 1,5 kb  
 DNA fragment obtained from *Bam*HI/*Spe*I digested pK18-ipdABsmegUP was  
 subsequently ligated into pK18-ipdABsmegUP linearized with *Bam*HI/*Spe*I, resulting in  
 the construction of pK18-ipdABsmeg used for *ipdAB* gene deletion.

15

**A8 Construction of plasmid for gene deletion of *fadE30* in *R. equi***

Plasmid pSelAct-fadE30 for the generation of an unmarked gene deletion of *fadE30* in  
 20 *R. equi* RE1 was constructed as follows. The upstream (1,511 bp; primers  
*fadE30equi*UP-F and *fadE30equi*UP-R) and downstream (1,449 bp; primers  
*fadE30equi*DOWN-F and *fadE30equi*DOWN-R) flanking genomic regions of *fadE30*  
 were amplified by a standard PCR using High Fidelity DNA polymerase (Fermentas  
 GmbH) (Table 5; PCR 15 and PCR 16). The obtained amplicons were ligated into the  
 25 pGEM-T cloning vector (Promega Benelux), rendering pGEMT-fadE30UP and pGEMT-  
*fadE30DOWN*. A 1.4 kb *Bcu*II/*Bgl*II DNA fragment was cut out of pGEMT-fadE30DOWN  
 and ligated into *Bcu*II/*Bgl*II linearized pGEMT-fadE30UP, resulting in pGEMT-fadE30. To  
 construct pSelAct-fadE30, pGEMT-fadE30 was digested with *Nco*I and *Bcu*II and treated  
 with Klenow fragment. A 2.9 kb blunt-end DNA fragment, carrying the *fadE30* gene  
 30 deletion, was ligated into *Sma*I digested pSelAct (van der Geize *et al.*, 2008). The  
 resulting plasmid was designated pSelAct-fadE30 and used for the construction of  
 mutant strain *R. equi*  $\Delta$ *fadE30*.

35

### **A9 Construction of plasmid for ipdAB gene deletion in *N. seriola* INS436**

Plasmid pK18ipdABNser, used for unmarked gene deletion of the *ipdAB* genes in *N.*  
 5 *seriola* INS436 was constructed as follows. The upstream (1,487 bp; primers  
*ipdABNserUP-F* and *ipdABNserUP-R*; PCR 24) and downstream (1,049 bp; primers  
*ipdABNserDOWN-F* and *ipdABNserDOWN-R*; PCR 25) flanking regions of the *ipdAB*  
 genes were amplified by PCR using genomic DNA of *N. seriola* INS436 as DNA  
 template (Table 5). The obtained amplicons were ligated into *Sma*I digested  
 10 pK18mobsacB (Schäfer *et al.*, 1994, in *Gene* **145**: 69-73)), resulting in pK18-  
*ipdABNserUP* and pK18-*ipdABNserDOWN*, respectively. A 1.07 kb DNA fragment  
 obtained from *Sma*I/*Pst*I digested pK18-*ipdABNserDOWN* was subsequently ligated into  
 pK18-*ipdABNserUP* which had been linearized with *Sma*I/*Pst*I, resulting in the  
 construction of plasmid pK18-*ipdABNser* that was used for *ipdAB* gene deletion.

15

### **A10 Construction of mutant strains *R. equi* $\Delta ipdAB$ and *R. equi* $\Delta ipdAB \Delta ipdAB2$**

*R. equi* unmarked gene deletion mutants of *ipdAB* (RG1341) and *ipdABipdAB2*  
 20 (RG2837) were constructed using a two-step homologous recombination strategy with  
 5-fluorocytosine counter-selection developed for *R. equi* (Van der Geize *et al.*, 2008).  
 For construction of the  $\Delta ipdAB$  mutant *R. equi* strain RG1341, the non-replicative  
 plasmid pSelAct-ipd1 was mobilized to *R. equi* strain RE1 by electrotransformation.  
 Four Apra<sup>R</sup> transformants, resulting from homologous recombination between plasmid  
 25 pSelAct-ipd1 and the RE1 genome, were subsequently subjected to 5-FC selection in  
 order to select for the occurrence of the second rare homologous recombination event  
 resulting in gene deletion. Eighteen randomly picked Apra<sup>S</sup>/5FC<sup>R</sup> colonies were  
 subjected to colony PCR and three FC<sup>R</sup>/Apra<sup>S</sup> colonies gave an amplicon of the  
 expected size (296 bp, Table 5, PCR5). Genomic DNA was isolated from these three  
 30  $\Delta ipdAB$  mutants and subjected to PCR analysis of the *ipdAB* locus and its up- and  
 downstream flanking regions (Table 5, PCR3 and PCR4). This analysis confirmed the  
 presence of a genuine *ipdAB* gene deletion in two out of three cases and revealed no  
 aberrant genomic rearrangements at the *ipdAB* locus. The presence of *vapA* as a  
 marker of the virulence plasmid was confirmed by PCR (Table 5, PCR11). One *ipdAB*  
 35 mutant strain was chosen, designated *R. equi* RG1341, and was used for further work.

Double gene deletion mutant strain RG2837 was constructed from strain RG1341 using plasmid pSelAct- $\Delta$ ipdAB2 essentially as described for the isolation of the  $\Delta$ ipdAB single mutant. Four Apra<sup>R</sup> transformants, obtained from electroporation of cells of strain RG1341 with pSelAct- $\Delta$ ipdAB2, were subjected to 5-FC selection to select for Apra<sup>S</sup>/5-FC<sup>R</sup> colonies. Subsequent PCR analysis of eighteen Apra<sup>S</sup>/5-FC<sup>R</sup> colonies confirmed that two colonies harbored a  $\Delta$ ipdAB2 gene deletion, as evident from the obtained 123 bp amplicon using oligonucleotide developed to amplify the ipdAB2 operon (Table 5, PCR10). Further analysis of the upstream and downstream regions of the ipdAB2 locus by PCR confirmed the presence of an ipdAB2 gene deletion and revealed no aberrant genomic rearrangements (Table 5, PCR8 and PCR9). Also, the presence of the vapA virulence gene was confirmed by PCR (Table 5, PCR11). One  $\Delta$ ipdAB $\Delta$ ipdAB2 double gene deletion mutant strain RG2837 was chosen for further work.

#### 15 **A11 Construction of mutant strain *M. smegmatis* $\Delta$ ipdAB**

An unmarked ipdAB gene deletion mutant of *M. smegmatis* mc<sup>2</sup>155 was constructed using the sacB counter selection system (Pelicic *et al.*, 1996, *Mol. Microbiol.* **20**:919-925; Van der Geize *et al.*, 2001, *FEMS Microbiol Lett.* **205**:197-202) as follows. For construction of the  $\Delta$ ipdAB mutant of *M. smegmatis* strain mc<sup>2</sup>155, the non-replicative plasmid pK18-ipdABsmeg was mobilized to *M. smegmatis* by electrotransformation. Several transformants were obtained. One kanamycin resistant transformant was grown for 2 days at 37°C non-selectively in TSB medium containing 0.05% Tween80 and subsequently plated onto TSB agar plates containing 2% sucrose to select for kanamycin sensitive (Km<sup>S</sup>) and sucrose resistant (Suc<sup>R</sup>) double-recombinants by sacB counter-selection. Colonies appearing after 3 days of incubation were replica streaked onto TSB agar and TSB agar supplemented with kanamycin (10 µg/ml) to select for Km<sup>S</sup>/Suc<sup>R</sup> colonies. Genuine Km<sup>S</sup>/Suc<sup>R</sup> colonies were further checked by colony PCR for the presence of the ipdAB gene deletion (Table 5, PCR14). Genomic DNA was isolated from three potential ipdAB mutants. PCR analysis confirmed the presence of the ipdAB gene deletion, and one ipdAB mutant strain was chosen for further work and designated *M. smegmatis*  $\Delta$ ipdAB.

#### 35 **A12 Construction of mutant strain *R. equi* $\Delta$ fadE30**

An unmarked gene deletion of *fadE30* in *R. equi* RE1 was generated using a two-step homologous recombination strategy with 5-fluorocytosine counter-selection developed for *R. equi* (Van der Geize *et al.*, 2008). For construction of the  $\Delta$ *fadE30* mutant strain, the non-replicative plasmid pSelAct-*fadE30* was mobilized to *R. equi* strain RE1 by electrotransformation. Two Apra<sup>R</sup> transformants, resulting from homologous recombination between plasmid pSelAct-*fadE30* and the RE1 genome, were subsequently subjected to 5-FC selection in order to select for the occurrence of the second rare homologous recombination event resulting in *fadE30* gene deletion. Eighteen randomly picked Apra<sup>S</sup>/5FC<sup>R</sup> colonies were subjected to colony PCR using primers *fadE30*cont-F and *fadE30*cont-R (Table 5; PCR 19) and thirteen FC<sup>R</sup>/Apra<sup>S</sup> colonies gave an amplicon of the expected size (428 bp). Genomic DNA was isolated from two potential  $\Delta$ *fadE30* mutants and subjected to PCR analysis. PCR analysis of the *fadE30* locus, using oligonucleotide primers *fadE30*contr-F and *fadE30*contr-R (Table 5), confirmed the presence of a *fadE30* gene deletion and the absence of the wild type *fadE30* gene. Analysis of the upstream and downstream flanking regions by PCR resulted in the expected 1.86 kb and 1.76 kb products, respectively. The analysis confirmed the presence of a genuine *fadE30* gene deletion in both cases and revealed no aberrant genomic rearrangements at the *fadE30* locus. The presence of *vapA* as a marker for the virulence plasmid was confirmed by PCR. One *fadE30* mutant strain was designated *R. equi*  $\Delta$ *fadE30* and was used for further work.

### **A13 Construction of mutant strain *N. seriola* $\Delta$ *ipdAB***

An unmarked *ipdAB* gene deletion mutant of *N. seriola* INS436 was constructed using the *sacB* counter selection system (Pelicic *et al.*, 1996, in *Mol. Microbiol.* **20**:919-925; Van der Geize *et al.*, 2001, in *FEMS Microbiol Lett.* **205**:197-202) as follows. The non-replicative plasmid pK18-*ipdAB*Nser was mobilized to *N. seriola* INS436 by electrotransformation. Several kanamycin resistant transformants were then grown non-selectively for 7 days at 26°C in Eugon broth medium containing 0.05% Tween80. Selection for kanamycin sensitive (Km<sup>S</sup>) and sucrose resistant (Suc<sup>R</sup>) double-recombinants by *sacB* counter-selection was subsequently performed by plating onto Eugon agar plates containing 2% sucrose. Colonies appearing after 7 days of incubation at 26°C were replica picked onto Eugon agar plates and Eugon agar plates supplemented with kanamycin (20 µg/ml), to select for Km<sup>S</sup>/Suc<sup>R</sup> colonies. Genuine Km<sup>S</sup>/Suc<sup>R</sup> colonies were further checked by colony PCR for the presence of the *ipdAB*

gene deletion using primers ipdABNser-F and ipdABNser-R (Table 5). Genomic DNA was isolated from three potential *ipdAB* mutants. PCR analysis using primer pair ipdABNser-F and ipdABNser-R (PCR 23) resulted in a 222 bp PCR product and the absence of a wild type 1,634 bp PCR product confirming the presence of the *ipdAB* gene deletion. Primer pair IpdABNser-F2 and IpdABNserDOWN-Contr-R (PCR 26) was used to further confirm the *ipdAB* gene deletion. This primer pair resulted in an expected PCR product of 1,148 bp for the *ipdAB* mutant, whereas a 2,560 bp PCR product was obtained only for the wild type strain. One mutant strain was designated *N. seriola*  $\Delta$ ipdAB and chosen for further work.

10

**PART B: MACROPHAGE SURVIVAL AS A MODEL FOR *IN VIVO* ATTENUATION****B1 Used strains**5     *Virulent strains*

Strain RE1: wildtype parent strain. This strain grows on cholesterol.

Strain RE1 $\Delta$ *supAB*: deletion of *supAB* gene. This strain is unable to grow on cholesterol.

*Non-virulent strain*

- 10     Strain 103- : lacks the 80- to 90-kb virulence plasmid and is known to be apathogenic in horses (Takai et al. 2000, Infect. Immun. 68: 6840-6847.). This strain grows on cholesterol.

*Strains according to the invention*

- 15     Strain RE1 $\Delta$ *ipdAB* (RG1341): the *ipdAB* gene in the cholesterol catabolic cluster is deleted. This strain does not grow on 4-androstene-3,17-dione (AD).

Strain RE1 $\Delta$ *ipdAB*-AD+: bacteria of strain RE1 $\Delta$ *ipdAB* adapted to grow on AD (if strain RE1 $\Delta$ *ipdAB* is plated in high concentration (more than 10<sup>6</sup> CFU/ml) with AD as the sole carbon source, then a few colonies may arise that do grow on AD).

- 20     Strain RE1 $\Delta$ *ipdABipdAB2* (RG2837): second set of *ipdAB* genes (not part of the cholesterol catabolic cluster) is also deleted. This strain does not grow on AD.

Strain *R. equi*  $\Delta$ *fadE30*. This strain is severely impaired for growth on HIP/HIL and AD.

**B2 Rhodococcus equi cultures for macrophage infection**

25

The different *Rhodococcus equi* strains to be tested in the macrophage survival assay were grown overnight (17h) at 37°C and 100 rpm in Nutrient Broth (Difco) aiming on a final concentration of 1-2 x 10<sup>8</sup> CFU/ml. Only freshly prepared cultures were used. After inoculation of the macrophages, a live count determination was done (plate counting) in

30     order to confirm the infectivity titer.

**B3 Rhodococcus cultures for foal challenge**

- 35     *Rhodococcus equi* strain RE1, RE1 $\Delta$ *ipdAB* and RE1 $\Delta$ *ipdAB*-AD+ were plated on blood agar and incubated for 24 hours at 37°C. Bacteria were harvested with 4 ml of sterile isotonic PBS per plate. The bacterial suspension was diluted with sterile isotonic PBS

aiming at a final concentration of  $4 \times 10^4$  CFU/ml. Transport was at ambient temperature; the diluted cultures were used within 4 hours after preparation. After challenge, a live count determination was done (plate counting) in order to confirm the infectivity titer. The live counts were  $4.35 \times 10^4$  CFU/ml for RE1,  $7.1 \times 10^4$  CFU/ml for RE1 $\Delta ipdAB$  and  $5.8 \times 10^4$  CFU/ml for RE1 $\Delta ipdAB$ -AD+, respectively.

#### **B4 Test systems**

##### *Macrophage cell line*

- 10 Cell line U937 (human monocyte) was used to test for survival of *Rhodococcus equi* strains. The monocytes were grown in RPMI 1640 + NaHCO<sub>3</sub> + NAPYR + glucose medium (RPMI 1640 medium), buffered with 10 mM HEPES and supplemented with 200 IU/ml penicillin and streptomycin and 10% fetal bovine serum (FBS). The cells were grown in suspension at 37°C and 5% CO<sub>2</sub>.

15

##### *Foals*

- Eight foals were used: seven 3 to 5-week-old foals and one 7 week-old (all with mare). The foals were allotted to three groups of 3, 3 and 2 foals, reckoning an even distribution of age over the groups. Housing was in isolation facilities. During the experiment the foals sucked and the mares were fed according to standard procedures. Fresh tap water was available ad libidum

Group	Mare	Foal ID No	Date of birth	gender
RE1	5977	17	10-05-08	male
	9263	18	17-05-08	female
	1952	19	19-04-08	male
RE1 $\Delta ipdAB$	6095	20	02-05-08	female
	3071	21	10-05-08	male
	9390	22	20-05-08	male
RE1 $\Delta ipdAB$ -AD+	8719	23	09-05-08	male
	4983	24	10-05-08	male



At T=0 all foals were challenged intratracheally with 100 ml challenge culture of strain RE1, RE1 $\Delta$ ipdAB or RE1 $\Delta$ ipdAB-AD+ (see here above under “Rhodococcus cultures for foal challenge”) using a syringe with needle, so called trans-tracheal injection.

5

## **B5 Experimental procedures and parameters**

### *Macrophage survival test*

For the macrophage survival assay, monocytes were grown for several days as described herein before. The culture medium was replaced with fresh culture medium and the cells were activated overnight with 60 ng/ml phorbol 12-myristate 13-acetate (PMA) to induce their differentiation to macrophages.

The differentiated cells were spun down (5 min. at 200xg) and the pellet was re-suspended in fresh, antibiotic free RPMI 1640 medium with 10% FBS. For each strain to be tested, a tube containing 10 ml of a cell suspension with approximately 10<sup>6</sup> cells/ml was inoculated with *Rhodococcus equi* at a multiplicity of infection (MOI) of approximately 10 bacteria per macrophage.

The bacteria were incubated with the macrophages for 1 hour at 37°C and 5% CO<sub>2</sub>. The medium was replaced with 10 ml RPMI 1640 medium supplemented with 10% FBS and 100 µg/ml gentamycin and incubated again for 1 hour to kill any extracellular bacteria. The macrophages (with internalized *R. equi*) were spun down (5 min. at 200xg) and the pellet was re-suspended in 40 ml RPMI 1640 medium, buffered with 10 mM HEPES and supplemented with 10% FBS and 10 µg/ml gentamycine. This suspension was divided over 4 culture bottles (10 ml each) and incubated at 37°C and 5% CO<sub>2</sub>. After 4, 28, 52 and 76 hours the macrophages (one culture bottle per strain) were spun down (5 min. at 200xg) and the pellet washed twice in 1 ml antibiotic free RPMI 1640 medium. Finally the pellet was lysed with 1% Triton X-100 in 0.01M phosphate buffered saline (PBS), followed by live count determination (plate counting).

30

### *Foal challenge*

1- Rectal temperature: measured day 1 before challenge, day of challenge (just before challenge) and then once daily after challenge until necropsy.

35

2- Clinical examination: during 3 weeks post-challenge the horses were daily examined for clinical signs.

3- Post mortem examination and bacteriology: on day 21 post-challenge the foals were weighed and then killed by anesthesia with xylazine (100 mg/100 kg) and ketamine (500 mg/100 kg) and subsequent bleeding to death. The lungs were weighed in order to calculate the lung to body weight ratio. A complete post-mortem examination was performed with special attention to the lungs and associated lymph nodes. In case of abnormalities, samples for histology were taken as deemed necessary by the pathologist.

Tissue samples (1 cm<sup>3</sup>) were excised from seven standard sites representative of the lobes of each half of the lung (3 sites per half + accessory lobe); diseased tissue was preferentially selected for each site, if it was present. The mirror image samples (the two samples of the equivalent lobe on each half) were pooled to give 3 samples per foal + a sample of the accessory lobe. Each (pooled) sample was homogenized, serially diluted and inoculated on blood agar plates and then incubated at 37°C for 16-24 hours. *Rhodococcus* colonies were enumerated and expressed as CFU/ml homogenate. Additional swabs were taken from all other abnormalities. Swabs were streaked on blood agar plates and then incubated at 37°C for 16-24 hours. *Rhodococcus equi* was initially identified by its typical non-hemolytic mucoid colony morphology. Further identification was done by Gram stain, API/ Phoenix, and/or PCR.

## **B6 Results**

### *Survival in macrophages*

The results of two separate experiments are shown in Table 1 (in conjunction with figure 1) and 2 (in conjunction with figure 2). The results show that the RE1Δ*supAB* mutant is able to survive in macrophages in a similar manner as the wild type parent strain RE1, indicating that cholesterol metabolism is not essential for macrophage survival. This is in line with the recognition that cholesterol metabolism as such is not important for virulence. In contrast, survival in macrophages of strain RE1Δ*ipdAB*, strain RE1Δ*ipdABipdAB2*, strain RE1Δ*ipdAB*-AD+ and strain 103-, was clearly reduced. Note however that the bacteria are still able to survive in the macrophages but at a

- significantly reduced level (typically at a concentration of 100 to 1000 times below the wild-type level). Strain 103- lacks the 80- to 90-kb virulence plasmid and is known to be avirulent in horses (Takai et al.). This strain 103- is not suitable as a vaccine strain since it does not induce a protective immune response, probably because it lacks the
- 5 virulence plasmid. In Table 9 (in conjunction with Figure 4) the results are shown for mutant strain *R. equi*  $\Delta$ fadE30 in comparison with the wild-type strain RE1 and strain RE1 $\Delta$ ipdAB. Clearly the fadE30 mutant has a survival characteristic comparable to the  $\Delta$ ipdAB strain, and is also less capable of surviving in the macrophages.
- 10 The results with strains that have a mutation in the operon that encodes a protein involved in methylhexahydroindanedione propionate degradation activity (i.e. strains RE1 $\Delta$ ipdAB, RE1 $\Delta$ ipdABipdAB2, RE1 $\Delta$ ipdAB-AD+ and *R. equi*  $\Delta$ fadE30) show that these strains are less capable to survive in macrophages, in particular, their survival capabilities are comparable to the survival capabilities of the apathogenic strain 103-.
- 15 This already is a good indication of adequate attenuation. Strain RE1 $\Delta$ ipdAB-AD+ demonstrated the same macrophage phenotype as strain RE1 $\Delta$ ipdAB indicating that it is an intact *ipdAB* operon rather than an intact cholesterol metabolism that is essential for macrophage survival at the wild-type level. The single *ipdAB* gene deletions (in the cholesterol catabolic gene cluster) resulted in a hampered macrophage survival. An
- 20 additional deletion in a copy of these genes (*ipdA* and *ipdB* outside the cholesterol catabolic cluster, called *ipdA2* and *ipdB2*) had no further attenuating effect in the macrophage test.
- Given these results, strains RE1 $\Delta$ ipdAB and RE1 $\Delta$ ipdAB-AD+ (= strain RE1 $\Delta$ ipdAB adapted to growth on AD) were administered intratracheally to foals (normal challenge
- 25 procedure) and compared with the wildtype parent strain RE1 to test for in vivo attenuation.

### *Rectal temperature*

- 30 In table 3 (in conjunction with figure 3) the results of the rectal temperature are presented. Group 1 is the Group that received the wild-type RE1 strain. Groups 2 and 3 received the RE1 $\Delta$ ipdAB and RE1 $\Delta$ ipdAB-AD+ respectively. The temperatures of days 3 to 10 are not shown since they did not reveal any significant changes from normal rectal
- 35 temperature. Abnormal temperatures are indicated in bold. Two of three foals (no. 18 and 19) challenged with the wild type parent strain RE1 showed clearly increased rectal

temperatures from 14 days post-challenge onwards. The increase in rectal temperature after 14 days coincided with the development of clinical signs (see below). Foal no. 21 (challenged with strain RE1 $\Delta$ ipdAB) showed a slightly increased temperature (39.1°C) at 1 day post-challenge which most probably is not related to *Rhodococcus* infection (incubation time in this challenge model normally is > 7 days). Further no increased temperatures were observed in the RE1 $\Delta$ ipdAB or RE1 $\Delta$ ipdAB-AD+ challenged foals.

#### *Clinical signs post-challenge*

10

Clinical scores from day 7 to 21 indeed showed that foal no. 18 and 19, challenged with wild type parent strain RE1 developed signs of respiratory disease from 13 days post-challenge onwards. Foal no. 17 (also RE1 challenge group) showed only mild clinical signs post-challenge. The foals which were challenged with mutant strain RE1 $\Delta$ ipdAB and RE1 $\Delta$ ipdAB-AD+ showed no clear signs of respiratory disease. The clinical effects of the latter two groups were mainly based on a slightly increased heart beat, which also (in part) could be due to handling stress, since it was also present before challenge.

#### 20 *Post-mortem examination*

The post-mortem findings with respect to the lungs are shown in Table 4. After challenge with the wild type parent strain RE1 the foals developed signs of respiratory disease (in particular foal no. 18 and 19). The foals challenged with mutant strains remained healthy. At 21 days post-challenge the foals were killed and necropsied. At post-mortem all foals challenged with the wildtype strain appeared to have typical pyogranulomatous pneumonia from which *R. equi* was re-isolated as a pure culture and the identity of the wildtype strain was confirmed by PCR. From foal no. 18 wild-type *R. equi* was also isolated from an enlarged mediastinal lymph node.

30 The lungs of the foals challenged with the mutant strains did not show pneumonic areas and *Rhodococcus* was not isolated, except from a slightly enlarged bronchial lymph node of foal no. 20, and from healthy lung tissue of foal no. 24. The identity of these isolates was confirmed as RE1 $\Delta$ ipdAB and RE1 $\Delta$ ipdAB-AD+ by PCR and growth on AD agar, respectively.

35

**B7 Conclusion for PART B of the experiments**

Strains RE1 $\Delta$ *ipdAB* and RE1 $\Delta$ *ipdAB-AD+* are clearly impaired in macrophage survival and are attenuated in foals. Knocking out the second copy of the *ipdAB* gene (resulting in  
5 RE1 $\Delta$ *ipdABipdAB2*) did not seem to have an additional effect in the macrophage survival test and probably also not in foals. The combined *in vivo* and *in vitro* results with strains RE1, RE1*supAB*, 103-, RE1 $\Delta$ *ipdAB* and RE1 $\Delta$ *ipdAB-AD+* indicate a good correlation between macrophage survival level and *in vivo* virulence for a bacterium belonging to the nocardioform actinomycetes. In particular, it appears that when a mutant strain has  
10 significantly reduced macrophage survival capabilities, typically about 2 to 3 logs with respect to the virulent parent strain, then the mutant strain is significantly attenuated with respect to the parent strain.

Based on the commonly known fact that the way of infection and virulency factors is  
15 shared among nocardioform Actinomycetes - hence the fact that *Rhodococcus equi* is commonly used as a model to study Mycobacteriaceae, in particular with respect to the virulence factors related to macrophage survival and persistency (see i.a. PNAS, February 6, 2007, vol. 104, no. 6, pp 1947-1952) - it is understood that the reduced survival rate for bacteria by inactivation of a gene that encodes a protein involved in  
20 methylhexahydroindanedione propionate degradation, is generic for attenuation of nocardioform actinomycetes.

## PART C: EFFICACY OF MUTANT BACTERIUM IN PROTECTION AGAINST INFECTION WITH WILD-TYPE

### 5 C1 Introduction

The efficacy with respect to a pharmaceutical composition containing live mutant bacteria according to the present invention is believed to be inherent. This can be understood by recognizing that the publicly available knowledge about mutations in the cholesterol metabolism clearly indicates that bacteria having mutations in the cholesterol metabolism still have an antigenic load comparable with that of wild-type organisms. In combination with the current knowledge, made available by the present invention, that the mutant live bacteria are still able to enter the macrophages and persist in them, it leaves no doubt that the stimulus of an immune response is secured. Still, applicant has conducted experiments to confirm this believe. For this, a vaccine containing live *Rhodococcus equi* was used. On itself, there is still no vaccine available against this bacterium which makes the experiments inherently relevant. But more importantly, this bacterium has been commonly recognised as a good model for other nocardioform actinomycetes, in particular *Mycobacterium tuberculosis*. Other confirming experiments (to obtain confirmatory results cover the complete range of nocardioform actinomycetes), could for example be done with *Nocardia seriolae* (see paragraph C6). This is a typical fish pathogen against which no adequate vaccine is available for the same reasons as why there is no adequate vaccine available against other macrophage surviving nocardioform actinomycetes.

### 25 C2 Experimental design

Sixteen 2 to 4-week-old foals were used for the study. The foals were divided in four groups of 4 foals and vaccinated orally with 1 ml vaccine containing different doses of RE1 $\Delta$ ipdAB (constituted in sterile isotonic phosphate buffered saline) Group 1 was vaccinated with  $5 \times 10^9$  CFU, group 2 was vaccinated with  $5 \times 10^8$  CFU; group 3 was vaccinated with  $5 \times 10^7$  CFU and group 4 was left as unvaccinated controls. Vaccinations were given at T=0 and at T=2 weeks. At T=4 weeks all foals were challenged intratracheally with 100ml culture of virulent *Rhodococcus equi* strain 85F (containing  $5 \times 10^6$  CFU per 100 ml dose).

During a period of 3 weeks after challenge the horses were clinically evaluated. The foals were weighed at day of first vaccination, day of challenge and at day of necropsy. At 3 weeks after challenge (or earlier in case of severe clinical signs) the foals were weighed and euthanized and a complete post-mortem examination was performed with special attention to the lungs and respiratory lymph nodes. The lungs were weighed in order to calculate the lung to body weight ratio. Tissue samples from all lung lobes were sampled for examination.

### **C3 Materials and Methods**

10

#### *Test articles*

The vaccine contained live *Rhodococcus* of strain RE1 $\Delta$ *ipdAB*, constituted in sterile isotonic phosphate buffered saline (PBS). The challenge culture was made as follows:

15 *Rhodococcus equi* strain 85F was plated on blood agar and incubated for 24 hours at 37°C. Bacteria were harvested with 4 ml of sterile isotonic PBS per plate. The bacterial suspension was diluted with sterile isotonic PBS aiming on a final concentration  $4 \times 10^4$  bacteria/ml. Transport was at ambient temperature; diluted culture was used within 4 hours after preparation. After challenge, a live count determination was done in order to confirm

20 the infectivity titer. The titer was  $5.3 \times 10^4$  CFU/ml.

#### *Experimental procedures and parameters*

Bacterial reisolation was performed by sampling rectal swabs just before each vaccination and on day 0, 1, 2, 3, 6, 10, 14, 15, 16, 17, 20 and 24 (after vaccination). Nasal swabs were sampled from the foals at T=0 (just before first vaccination). The swab samples were serially diluted in physiological salt solution and plated on bloodagar and incubated at 37°C for 16-24 hours. *Rhodococcus* colonies were initially identified by the typical non-hemolytic mucoid colony morphology, enumerated and expressed as CFU/ml. On each isolation day

30 three re-isolates were selected at random (from three different horses if present) were used to confirm the identity: Gram stain, API/Phoenix and PCR on *ipdAB* genes.

During the study the horses were daily observed for any abnormalities of general health and/or behavior by a biotechnician. Starting one day before challenge the horses were

35 daily examined (until necropsy) for clinical signs. Weighing took place just before first

vaccination, just before challenge and just before necropsy. This way, the weight gain and the lung to body weight ratio could be calculated.

On day 14-20 post-challenge (or earlier in case of severe clinical signs) the foals were  
5 killed by anesthesia with xylazine (100 mg/100 kg) and ketamine (500 mg/100 kg) and  
subsequent bleeding to death. The lungs were weighed in order to calculate the lung to  
body weight ratio. A complete post-mortem examination was performed. Tissue  
samples (1 cm<sup>3</sup>) were excised from seven standard sites representative of the lobes of  
each half of the lung (3 sites per half + accessory lobe); diseased tissue was  
10 preferentially selected for each site, if it was present. The mirror image samples (the two  
samples of the equivalent lobe on each half) were pooled to give 3 samples per foal + a  
sample of the accessory lobe. Each (pooled) sample was homogenized, serially diluted  
and inoculated on blood agar plates and then incubated at 37°C for 16-24 hours.  
*Rhodococcus* colonies were enumerated and expressed as CFU/ml homogenate. The  
15 pneumonia lung score for each animal was obtained by establishing for the apical (left +  
right), caudal (left + right) and accessory lung nodes the percentage of consolidation.  
For each animal, these percentages were added to obtain one lung score figure. This  
way, a lung score between 0 and 500 is obtained.

20

#### **C4 Results**

The post-challenge results are summarized in Table 7. From the summarized results it  
is clear that all four controls developed severe signs of pyogranulomatous pneumonia  
25 caused by *R. equi* as the sole pathogen. Two vaccinates no. 4 and 5 had signs  
comparable to the controls but all other vaccinates had much milder signs or virtually no  
signs. The % lung weight (an objective measure for the amount of pneumonia) confirms  
the partial protection in most of the vaccinates.

Vaccinated foal no. 2 had pneumonia caused by aspecific bacteria. In fact this foal can  
30 be regarded as protected since *Rhodococcus* was not isolated despite the massive  
challenge. In addition, from three vaccinated foals with pneumonia, mixed infections  
were isolated. These mixed infections probably have negatively influenced the different  
protection parameters. Although the protective effect of the vaccine is evident, no dose  
response effect was observed. In fact, the lowest dose appeared to provide the best  
35 results. Based on this, in conjunction with the fact that foals have an immature



gastrointestinal flora, it is believed that an optimum dose lies between  $1 \times 10^4$  and  $1 \times 10^{10}$  CFU.

## 5 **C5 Conclusion for part C of the experiments**

All three oral doses of the vaccine appeared to be safe for young foals and induced substantial protection against a severe intratracheal challenge. In the current experiments the genes ipdA and ipdB of the ipdAB operon were both removed from the genome of the bacteria in the vaccine. It is clear however that other mutations involving the same operon can be equally effective. A mutation which for example affects only one of the genes ipdA or ipdB can be equally effective per se. In any of the latter cases, the transferase involved cannot be made and thus the same phenotype is arrived at. Indeed this can also be derived from Rengarajan (PNAS, June 7, 2005, Vol. 102, No. 23, pp 8327-8332). In this reference relevant proof is provided for another nocardioform actinomycete, viz. *Mycobacterium tuberculosis*: inactivating either one of the orthologous ipd genes (called rv3551 and rv3552 respectively in *M. tuberculosis*) results in the same phenotype.

20

## **C6 Confirmation of vaccine efficacy of a *Nocardia seriolae* mutant**

The above experiments for *Rhodococcuse equi* were repeated for another actinomycete, the fish pathogen *Nocardia seriolae*, which causes nocardiosis in fish. For this experiment the wildtype strain INS436 and the  $\Delta$ ipdAB strain as mentioned here-  
above in parargraph A13 were used.

Groups of 20 yellowtail fish (*Seriola quinqueradiata*) were IP-injected with either the wild-type strain or mutant strain (at various concentrations), and one group of 20 fish was left as control. The fish were observed for the occurence of mortality and other clinical reactions for 2-3 weeks to evaluate attenuation of the mutant strain. At the end of this observation period surviving fish were challenged with a fixed dose of the wild type strain to evaluate efficacy of the mutant strain as a vaccine. Fish were observed for another 2 weeks.

For the wildtpe strain an inoculum was made of  $2.25 \times 10^8$  cfu/ml. For the mutant strain this was  $7.85 \times 10^8$  cfu/ml (about 3 times higher). Of these neat inoculums, 2-fold, 20-fold,

200-fold and 2000-fold dilutions were made for use in the attenuation study. The IP-challenge material contained  $1.2 \times 10^6$  cfu/ml.

- 5 The results for the attenuation experiment are indicated in Table 10 (which shows the mortality at the end of the observation period). From this it becomes clear that the mutant strain is attenuated with respect to the wild-type strain: Although the neat inoculum for the mutant strain was three times higher in cfu's/ml, the mortality is significantly lower in the group that received the mutant strain. The results for the efficacy experiment are indicated in Table 11. Although no complete protection could be
- 10 obtained, it is clear that the mutant provides significant protection (given the fact that in the control group 60 percent of the fish died during the observation period). Even in the group of fish that received the 2000-fold dilution, far less fish died because of the challenge with wild type *Nocardia seriolae*.
- 15 It has thus been shown that inactivation of a gene that encodes a protein involved in methylhexahydroindanedione propionate degradation, leads to an attenuated and protective vaccine strain in a second nocardioform actinomycete. This is further support for the fact that the invention is applicable over the whole range of nocardioform actinomycetes.

**PCT**

Print Out (Original in Electronic Form)

(This sheet is not part of and does not count as a sheet of the international application)

<b>0-1</b>	<b>Form PCT/RO/134 (SAFE) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)</b>	
0-1-1	Prepared Using	<b>PCT Online Filing Version 3.5.000.204 MT/FOP 20020701/0.20.5.9</b>
<b>0-2</b>	<b>International Application No.</b>	
<b>0-3</b>	<b>Applicant's or agent's file reference</b>	<b>2009.001 WO</b>

<b>1</b>	<b>The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:</b>	
<b>1-1</b>	<b>page</b>	<b>9 and 15</b>
<b>1-2</b>	<b>line</b>	<b>16 ; 17,18,32</b>
<b>1-3</b>	<b>Identification of deposit</b>	
1-3-1	Name of depositary institution	<b>CNCM Collection nationale de cultures de micro-organismes</b>
1-3-2	Address of depositary institution	<b>Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France</b>
1-3-3	Date of deposit	<b>07 January 2009 (07.01.2009)</b>
1-3-4	Accession Number	<b>CNCM I-4108 and I-4109</b>
<b>1-5</b>	<b>Designated States for Which Indications are Made</b>	<b>All designations</b>

**FOR RECEIVING OFFICE USE ONLY**

<b>0-4</b>	<b>This form was received with the international application: (yes or no)</b>	
0-4-1	Authorized officer	

**FOR INTERNATIONAL BUREAU USE ONLY**

<b>0-5</b>	<b>This form was received by the international Bureau on:</b>	
0-5-1	Authorized officer	

**CLAIMS**

1. Pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes  
5 having the ability to survive within macrophages of the animal, comprising live bacteria of a nocardioform actinomycetes species, the live bacteria being attenuated by inactivation of a gene that encodes a protein involved in methylhexahydroindanedione propionate degradation, and a pharmaceutically acceptable carrier for these live bacteria.
- 10 2. Pharmaceutical composition according to claim 1, characterised in that multiple genes in an operon are inactivated.
3. Pharmaceutical composition according to claim 2, characterised in that the genes  
15 ipdA and ipdB are inactivated.
4. Pharmaceutical composition according to any of the preceding claims, wherein inactivation is realised by deleting at least one gene by unmarked gene deletion.
- 20 5. Pharmaceutical composition according to any of the preceding claims, characterised in that the bacteria belong to the family of Nocardiaceae or Mycobacteriaceae.
6. Pharmaceutical composition according to claim 5, characterised in that the bacteria belong to the genera *Rhodococcus*, *Nocardia* or *Mycobacterium*.
- 25 7. Pharmaceutical composition according to claim 6, characterised in that the bacteria belong to the species *Rhodococcus equi*, *Nocardia seriolae*, *Mycobacterium tuberculosis*, *Mycobacterium ulcerans*, *Mycobacterium bovis* or *Mycobacterium avium paratuberculosis*.
- 30 8. Pharmaceutical composition according to any of the preceding claims, characterised in that it is in a form suitable for oral administration.
9. Pharmaceutical composition according to any of the preceding claims, characterised  
35 in that the live bacteria are present in a concentration between  $1 \times 10^4$  and  $1 \times 10^{10}$  CFU per dose.

10. *Rhodococcus equi* bacteria derived from a strain as deposited with the Collection Nationale de Cultures de Micro-organismes of the Institut Pasteur at Paris France under nr. CNCM I-4108 or nr. CNCM I-4109.

5

11. *Rhodococcus equi* bacteria of a strain as deposited with the Collection Nationale de Cultures de Micro-organismes of the Institut Pasteur at Paris France under nr. CNCM I-4108 or nr. CNCM I-4109.

10 12. Use of live bacteria that belong to the group of nocardioform actinomycetes having the ability to survive within macrophages of an animal, the live bacteria being attenuated by inactivation of a gene that encodes a protein involved in methylhexahydroindanedione propionate degradation , to manufacture a pharmaceutical composition to protect an animal against a disorder arising from an infection with a  
15 corresponding wild-type bacterium.

13. Method of treating an animal to protect it against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes having the ability to survive within macrophages of an animal, comprising administering to the  
20 animal a pharmaceutical composition comprising live bacteria of a nocardioform actinomycetes species, which live bacteria are attenuated by inactivation of a gene that encodes a protein involved in methylhexahydroindanedione propionate degradation.

**Table 1** Survival of *R. equi* mutants in macrophages

strain	log CFU/ml at ... hours post-infection				
	0	4	28	52	76
<b>RE1</b>	6.7	5.4	6.1	6.2	6.0
<b>RE1<math>\Delta</math>supAB</b>	6.6	5.3	5.9	6.1	6.1
<b>RE1<math>\Delta</math>ipdAB</b>	6.6	1.7	1.7	2.2	0
<b>RE1<math>\Delta</math>ipdABipdAB2</b>	6.7	2.3	2.9	3.7	3.8
<b>103-</b>	6.7	3.9	1.7	2.5	2.7



**Fig. 1**

Table 2 Survival of *R. equi* mutants in macrophages

strain	log CFU/ml at ... hours post-infection				
	0	4	28	52	76
RE1	6.6	4.6	5.0	5.4	5.4
RE1 $\Delta$ supAB	6.6	4.7	4.9	5.4	5.5
RE1 $\Delta$ ipdAB	6.6	2.7	2.7	3.4	3.7
RE1 $\Delta$ ipdAB-AD+	6.5	3.1	3.4	3.8	4.0
103-	6.5	5.2	3.7	3.0	3.1

Fig 2




**Table 3 Rectal temperature post-challenge**

group	foal no	Rectal temperature at post-challenge day																		
		-1	0	1	2	11	12	13	14	15	16	17	18	19	20	21				
RE1	17	38.5	38.4	38.6	38.4	38.3	38.3	38.2	38.3	38.5	38.6	38.6	38.7	38.6	38.5	38.2				
	18	38.5	38.4	38.5	38.3	38.4	38.5	38.3	38.2	38.6	38.6	<b>39.4</b>	<b>39.9</b>	<b>40.4</b>	<b>40.4</b>	<b>40.3</b>				
	19	38.3	38.0	38.6	37.9	38.4	38.7	38.7	<b>39.1</b>	<b>39.1</b>	38.8	<b>39.7</b>	<b>39.6</b>	<b>39.1</b>	38.8	38.0				
	mean	38.4	38.3	38.6	38.2	38.4	38.5	38.4	38.5	38.7	38.7	<b>39.2</b>	<b>39.4</b>	<b>39.4</b>	<b>39.2</b>	38.8				
RE1ΔipdAB	20	38.5	38.5	38.8	38.4	38.5	38.2	38.4	38.2	38.4	38.3	38.1	38.5	38.4	38.4	38.4				
	21	38.6	37.9	<b>39.1</b>	38.4	38.3	38.2	38.3	38.4	38.6	38.0	38.2	38.3	38.0	38.1	38.1				
	22	38.5	38.6	38.7	38.5	38.4	38.2	38.4	38.4	38.4	38.4	38.4	38.5	38.5	38.4	38.5				
	mean	38.5	38.3	38.9	38.4	38.4	38.2	38.4	38.3	38.5	38.2	38.2	38.4	38.3	38.3	38.3				
RE1ΔipdAB-AD+	23	38.8	38.2	38.7	38.2	38.5	38.5	38.4	38.2	38.4	38.5	38.6	38.2	38.1	38.2	38.0				
	24	38.5	38.2	38.5	38.1	38.3	38.3	38.2	38.2	38.1	38.2	38.2	38.1	38.0	38.1	37.9				
	mean	38.7	38.2	38.6	38.2	38.4	38.4	38.3	38.2	38.3	38.4	38.4	38.2	38.1	38.2	38.0				



Fig. 3



**Table 4 Lung scores**

group	foal no	% consolidation / pneumonia per lung lobe					total
		apical L	apical R	caudal L	caudal R	accessory	
RE1	17	5	30	5	30	30	100
	18	10	0	60	40	70	180
	19	50	70	50	70	90	330
	mean	22	33	38	47	63	203
RE1 $\Delta$ ipdAB	20	0	0	0	0	0	0
	21	0	0	0	0	0	0
	22	0	0	0	0	0	0
	mean	0	0	0	0	0	0
RE1 $\Delta$ ipdAB-AD+	23	0	0	0	0	0	0
	24	0	0	0	0	0	0
	mean	0	0	0	0	0	0

Table 5. Oligonucleotides used for PCR.

PCR	PCR Amplicon	Size (bp)	Oligonucleotide sequence	(SEQ ID NO)
1	Upstream region <i>R. equi</i> RE1 <i>ipdAB</i> (construction pSelAct- <i>ipd1</i> )	1,368	<i>ipdABequi</i> UP-F TGCCGCTGACGGAGGAGATCAT <i>ipdABequi</i> UP-R GATATCATACCGGGACTGCCTCATCCA	(5) (6)
2	Downstream region <i>R. equi</i> RE1 <i>ipdAB</i> (construction pSelAct- <i>ipd1</i> )	1,396	<i>ipdABequi</i> DOWN-F GATATCGAACCAACCCGTGGTCACCAAC <i>ipdABequi</i> DOWN-R TCGAGCAGCGAACTGGCCTGAA	(7) (8)
3	Upstream region <i>R. equi</i> RE1 <i>ipdAB</i> (confirmation $\Delta$ <i>ipdAB</i> mutant)	1,726 (wt: 3,067)	<i>ipdABequi</i> ContrUP-F AGTCCGACGACGATCGAGTTGA <i>ipdABequi</i> Contr-R TCACGCCGAGACCTCACGGTCA	(9) (10)
4	Downstream region <i>R. equi</i> RE1 <i>ipdAB</i> (confirmation $\Delta$ <i>ipdAB</i> mutant)	1,682 (wt: 3,023)	<i>ipdABequi</i> Contr-F ATGGCTGAGAAGCCGCGACAAGC <i>ipdABequi</i> ContrDOWN-R TCGTCGTCGTCGCAACCAT	(11) (12)
5	<i>ipdAB</i> operon <i>R. equi</i> RE1 (confirmation $\Delta$ <i>ipdAB</i> mutant)	296 (wt: 1,636)	<i>ipdABequi</i> Contr-F2 ATGGCTGAGAAGCCGCGACAAGC <i>ipdABequi</i> Contr-R2 TCACGCCGAGACCTCACGGTCA	(13) (14)
6	Upstream region <i>R. equi</i> RE1 <i>ipdAB2</i> (construction pSelAct- $\Delta$ <i>ipdAB2</i> )	1,444	<i>ipdAB2equi</i> UP-F TCGAGGTGTTTCATGACGAAGA <i>ipdAB2equi</i> UP-R AGATCTCCGCGCCGACCACTCTTTCTCC	(15) (16)
7	Downstream region <i>R. equi</i> RE1 <i>ipdAB2</i> (construction pSelAct- $\Delta$ <i>ipdAB2</i> )	1,387	<i>ipdAB2equi</i> DOWN-F AGATCTAGTCCGAGGAGCTGGAACCTGA <i>ipdAB2equi</i> DOWN-R ACTAGTGATCTCGTCCGTGACCTGATG	(17) (18)
8	Upstream region <i>R. equi</i> RE1 <i>ipdAB2</i> (confirmation $\Delta$ <i>ipdAB2</i> mutant)	1,557 (wt: 3,053)	<i>ipdAB2</i> ContrUP-F CCGACATCACGGGTGTCGGGATC <i>ipdAB2</i> Contr-R TCACGCCGGAACCTCCTTTGTCG	(19) (20)
9	Downstream region <i>R. equi</i> RE1 <i>ipdAB2</i> (confirmation $\Delta$ <i>ipdAB2</i> mutant)	1,471 (wt: 2,967)	<i>ipdAB2</i> Contr-F TTGTCGGACAAGAGAATGTCCG <i>ipdAB2</i> ContrDOWN-R GGTCGTGACGTCCGCGGTGTTTC	(21) (22)
10	<i>ipdAB2</i> operon <i>R. equi</i> RE1 (confirmation $\Delta$ <i>ipdAB2</i> mutant)	123 (wt: 1,619)	<i>ipdAB2</i> contr-F TTGTCGGACAAGAGAATGTCCG <i>ipdAB2</i> contr-R TCACGCCGGAACCTCCTTTGTCG	(23) (24)
11	<i>vapA R. equi</i> RE1	408	<i>vapA</i> -F GCAGCAGTGCGATTCTCAATAG <i>vapA</i> -R TAACTCCACCGGACTGGATATG	(25) (26)
12	Upstream region <i>ipdAB</i> genes <i>M. smegmatis</i> <i>mc</i> <sup>2</sup> 155 (construction pK18- <i>ipdABsmeg</i> )	1,502	<i>ipdABsmeg</i> UP-F TTCGAGATGGCCGCGATCGAAT <i>ipdABsmeg</i> UP-R ACTAGTGATGGTTCATGCCGCTCTCGATA	(27) (28)
13	Downstream region <i>ipdAB</i> genes <i>M. smegmatis</i> <i>mc</i> <sup>2</sup> 155 (construction pK18- <i>ipdABsmeg</i> )	1,431	<i>ipdABsmeg</i> DOWN-F ACTAGTCAGGTCCGCCGACACACCTCGT <i>ipdABsmeg</i> DOWN-R AAGCTTGAATTCGTCCGCCGACGGTGAAG	(29) (30)
14	<i>ipdAB</i> operon <i>M. smegmatis</i> <i>mc</i> <sup>2</sup> 155 (confirmation $\Delta$ <i>ipdAB</i> mutant)	273 (wt: 1,697)	<i>ipdABsmeg</i> cont-F ACGCCAGCTACCGCATGGAA <i>ipdABsmeg</i> cont-R ATCACCTCGCGCAGCAGCTT	(31) (32)

Table 5 (continued). Oligonucleotides used for PCR.

PCR	PCR Amplicon	Size (bp)	Oligonucleotide sequence (nr.)	(SEQ ID NO)
15	Upstream region <i>R. equi</i> RE1 <i>fadE30</i> (construction pSelAct- <i>fadE30</i> )	1,511	<i>fadE30</i> equiUP-F TCCATTGCGCGCAGCGCATTCCT	(33)
			<i>fadE30</i> equiUP-R AGATCTCTCGAGCCATTCGCGAAT	(34)
16	Downstream region <i>R. equi</i> RE1 <i>fadE30</i> (construction pSelAct- <i>fadE30</i> )	1,449	<i>fadE30</i> equiDOWN-F AGATCTACGGCGGATCCAAACGAGAT	(35)
			<i>fadE30</i> equiDOWN-R AGGTGCGGGAACCTCTGGTTAC	(36)
17	Upstream region <i>R. equi</i> RE1 <i>fadE30</i> (confirmation <i>fadE30</i> mutant)	1,866 (wt: 2,909)	<i>fadE30</i> UPcontr-F ACGATGTACGCACGACCGACCT	(37)
			<i>fadE30</i> contr-R GACAGCTTCTCGACGGTCTCAC	(38)
18	Downstream region <i>R. equi</i> RE1 <i>fadE30</i> (confirmation <i>fadE30</i> mutant)	1,767 (wt: 2,811)	<i>fadE30</i> contr-F AGGCGAGGCGGAACTCTATAC	(39)
			<i>fadE30</i> DOWNcontr-R CGTCCAGAACGATGGAGAGTA	(40)
19	<i>fadE30</i> locus <i>R. equi</i> RE1 (confirmation <i>fadE30</i> mutant)	428 (wt: 1,470)	<i>fadE30</i> cont-F AGGCGAGGCGGAACTCTATAC	(41)
			<i>fadE30</i> cont-R GACAGCTTCTCGACGGTCTCAC	(42)
20	Upstream region of <i>ipdAB</i> of <i>N. seriola</i> INS436 for sequence determination <i>ipd</i> locus	1,644	<i>ipd</i> -actino-F2 GGTGGTCTTCGCCGCCGCCGCGTG	(44)
			<i>ipd</i> A-actino-R CGATGCCGATGTCATGCCGCT	(45)
21	Downstream region of <i>ipdAB</i> of <i>N. seriola</i> INS436 for sequence determination <i>ipd</i> locus	1,381	<i>ipd</i> B-actino-F GGCAACCAGAACCTCTCCGCCCTTCGG	(46)
			<i>ipd</i> -actino-R GTGTGCCCTCGACCAGGCCGCCGCAACAGCAT	(47)
22	Part of <i>ipdAB</i> genes of <i>N. seriola</i> INS436 for sequence determination <i>ipd</i> locus	1,162	<i>ipd</i> A-actino-F AGCGGCATGACCATCGGCATCG	(48)
			<i>ipd</i> B-actino-R CCGAAGGCGGAGAGTTCTGGTTGCC	(49)
23	<i>ipdAB</i> genes of <i>N. seriola</i> INS436 for sequence determination <i>ipd</i> locus and to confirm <i>ipdAB</i> gene deletion	222 (wt: 1,634)	<i>ipd</i> ABNser-F ATGCGCGACAAGCGAATGAGCCT	(50)
			<i>ipd</i> ABNser-R TCATGCCGTCACCTTCCCTTCCCG	(51)
24	Upstream region of <i>ipdAB</i> for construction of plasmid for <i>ipdAB</i> gene deletion	1,487	<i>ipd</i> ABNserUP-F TCCTCGTCGCCGTAGTGCAGGT	(52)
			<i>ipd</i> ABNserUP-R CCCGGGATGGTTCATGCCGTGCGGAGC	(53)
25	Downstream region of <i>ipdAB</i> for construction of plasmid for <i>ipdAB</i> gene deletion	1,049	<i>ipd</i> ABNserDOWN-F CCCGGGTGTGTCGCCGCGACGAG	(54)
			<i>ipd</i> ABNserDOWN-R TTGGCGGCCATGATGACCTGGG	(55)
26	Downstream region of <i>ipdAB</i> to confirm <i>ipdAB</i> gene deletion	1,148 (wt: 2,560)	<i>ipd</i> ABNser-F2 ATGCGCGACAAGCGAATGAGCCT	(56)
			<i>ipd</i> ABNserDOWN-Contr-R GCCTTCCACCAGACCGGCTTTG	(57)

**Table 6. Overview of genes**

Actinobacterial strain	IpdA		IpdB	
	Gene ID	Protein Identity (%)	Gene ID	Protein Identity (%)
<i>Rhodococcus equi</i> 103S	<i>ipdA</i>	100	<i>ipdB</i>	100
<i>Rhodococcus equi</i> 103S	<i>ipdA2</i>	55	<i>ipdB2</i>	51
<i>Rhodococcus jostii</i> RHA1	<i>Ro04651</i>	79	<i>Ro04650</i>	77
<i>Rhodococcus erythropolis</i> SQ1	<i>ipdA</i>	76	<i>ipdB</i>	74
<i>Mycobacterium tuberculosis</i> H37Rv	<i>Rv3551</i>	69	<i>Rv3552</i>	67
<i>Mycobacterium bovis</i> AF2122/97	<i>Mb3581</i>	69	<i>Mb3582</i>	67
<i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> K-10	<i>MAP0515c</i>	72	<i>MAP0514c</i>	68
<i>Mycobacterium avium</i> 104	<i>MAV_0609</i>	72	<i>MAV_0608</i>	68
<i>Mycobacterium ulcerans</i> Agy99	<i>MUL_4114</i>	67	<i>MUL_4115</i>	66
<i>Mycobacterium marinum</i> M	<i>MMAR_5040</i>	69	<i>MMAR_5041</i>	65
<i>Mycobacterium vanbaalenii</i> PYR-1	<i>Mvan_5267</i>	71	<i>Mvan_5268</i>	67
<i>Mycobacterium gilvum</i> PYR-GCK	<i>Mflv_1489</i>	72	<i>Mflv_1488</i>	68
<i>Mycobacterium</i> sp. MCS	<i>Mmcs_4684</i>	71	<i>Mmcs_4685</i>	70
<i>Mycobacterium</i> sp. JLS	<i>Mjls_5069</i>	71	<i>Mjls_5070</i>	70
<i>Mycobacterium smegmatis</i> MC2 155	<i>MSMEG_6002</i>	72	<i>MSMEG_6003</i>	69
<i>Mycobacterium abscessus</i>	<i>MAB_0605c</i>	73	<i>MAB_0604c</i>	74
<i>Nocardia farcinica</i> IFM 10152	<i>Nfa5090</i>	71	<i>Nfa5080</i>	72

**Table 7 Summary results after challenge**


group	foal no	daily weight gain after challenge	% lung weight per total weight at post- mortem	pneumonia  lung score	mean isolation <i>R.</i> <i>equi</i>  from lung  log <sub>10</sub> CFU/ml
group 1	1	0.24	1.6%	126	4.75
	2	0.06 <sup>a</sup>	1.4% <sup>a</sup>	25 <sup>a</sup>	0
	3	0.24	1.2%	14	0.98
	4	0.31	1.9%	211	5.88
	mean	0.26	1.6%	117	2.90
group 2	5	-0.06	3.1%	335	7.09
	6	0.45	1.1%	8	1.24
	7				
	8	0.18	1.9%	166	5.34
	mean	0.19	2.0%	170	4.56
group 3	9	0.25	1.4%	95	2.36
	10	0.44	1.0%	4	0
	11	0.27	1.2%	93	2.82
	12	0.31	1.1%	0	0
	mean	0.31	1.2%	48	1.30
controls	13	0.13	2.6%	320	8.82
	14	0.21	2.0%	230	6.96
	15	0.10	3.4%	300	8.91
	16	0.01	2.9%	230	5.91
	mean	0.11	2.7%	270	7.65

**Table 8. Overview of genes**

Actinobacterial strain	FadE30	
	Gene ID	Protein Identity (%)
<i>Rhodococcus equi</i> 103S	<i>fadE30</i>	100
<i>Rhodococcus opacus</i> B4	<i>ROP_45410</i>	74
<i>Rhodococcus jostii</i> RHA1	<i>Ro04596</i>	75
<i>Rhodococcus erythropolis</i> PR4	<i>RER_08910</i>	72
<i>Mycobacterium tuberculosis</i> H37Rv	<i>Rv3560c</i>	68
<i>Mycobacterium bovis</i> AF2122/97	<i>Mb3590c</i>	68
<i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> K-10	<i>MAP0507</i>	69
<i>Mycobacterium ulcerans</i> Agy99	<i>MUL_4125</i>	69
<i>Mycobacterium marinum</i> M	<i>MMAR_5049</i>	69
<i>Mycobacterium vanbaalenii</i> PYR-1	<i>Mvan_5285</i>	69
<i>Mycobacterium gilvum</i> PYR-GCK	<i>Mflv_1481</i>	69
<i>Mycobacterium</i> sp. MCS	<i>Mmcs_4693</i>	68
<i>Mycobacterium smegmatis</i> MC2 155	<i>MSMEG_6012</i>	66
<i>Mycobacterium abscessus</i>	<i>MAB_0597</i>	71
<i>Nocardia farcinica</i> IFM 10152	<i>Nfa4840</i>	76
<i>Salinispora tropica</i> CNB-440	<i>Strop_2615</i>	64
<i>Salinispora arenicola</i> CNS-205	<i>Sare_2814</i>	65
<i>Streptomyces avermitilis</i> MA-4680	<i>SAV_3834</i>	59
<i>Nocardioides</i> sp. JS614	<i>Noca_2767</i>	65

**Table 9 Survival of *R. equi* mutants in macrophages**

strain	log CFU at .... hours post-infection				
	0	4	28	52	76
RE1	6.7	4.9	4.9	5.2	5.2
RE1 $\Delta$ ipdAB	6.4	2.8	2.7	3.1	3.0
RE1 $\Delta$ fadE30	6.4	3.3	2.5	2.8	2.6





**Table 10. Mortality of fish (percentage) after administration of wild-type and mutant *N. seriolae* strain**

	Wild-type	Mutant
2-fold dilution	80%	50%
20-fold dilution	35%	25%
200-fold dilution	5%	0%
2000-fold dilution	0%	0%

5

**Table 11. Mortality of vaccinated fish (percentage) after challenge with wild-type *N. seriolae***

10

<b>2-fold dilution</b>	<b>10%</b>
<b>20-fold dilution</b>	<b>15%</b>
<b>200-fold dilution</b>	<b>15%</b>
<b>2000-fold dilution</b>	<b>20%</b>
<b>Control</b>	<b>60%</b>

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2010/050196

### Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
  - a. (means)  
☐ on paper  
☒ in electronic form
  - b. (time)  
☒ in the international application as filed  
☐ together with the international application in electronic form  
☐ subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2010/050196

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. A61K35/74 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2008/070039 A (UNIV NEW YORK [US]; SAMPSON NICOLE [US]) 12 June 2008 (2008-06-12) *cf. abstract, page 2, lines 13-15, page 20, lines 9-14, claim 1*	1-13
A	WO 99/05304 A (UNIV TEMPLE [US]; MOSSER DAVID M [US]) 4 February 1999 (1999-02-04) *cf. abstract, page 1, lines 10-21, page 7, lines 11-28, page 11, lines 5-12, claim 1*	1-13

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
"&" document member of the same patent family

Date of the actual completion of the international search

15 March 2010

Date of mailing of the international search report

19/03/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Stoltner, Anton

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2010/050196

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2008070039	A	12-06-2008	NONE	
WO 9905304	A	04-02-1999	AU	8604698 A 16-02-1999
			CA	2298558 A1 04-02-1999